Literature DB >> 23797883

Splenic vein thrombosis is associated with an increase in pancreas-specific complications and reduced survival in patients undergoing distal pancreatectomy for pancreatic exocrine cancer.

Nishi Dedania1, Nidhi Agrawal, Jordan M Winter, Leonidas G Koniaris, Ernest L Rosato, Patricia K Sauter, Ben Leiby, Edward Pequignot, Charles J Yeo, Harish Lavu.   

Abstract

Distal pancreatectomy and splenectomy (DPS) is the procedure of choice for the surgical treatment of pancreatic exocrine cancer localized to the body and tail of the pancreas. Splenic vein thrombosis (SVT) can occur in patients with malignant pancreatic exocrine tumors secondary to direct tumor invasion or compression of the splenic vein by mass effect. This study examines the effect of preoperative SVT on postoperative outcomes. In this retrospective cohort study, we queried our pancreatic surgery database to identify patients who underwent DPS from October 2005 to June 2011. These cases were evaluated for evidence of preoperative SVT on clinical records and cross-sectional imaging (CT,MRI, endoscopic US). Outcomes for patients with and without SVT were compared. From an overall cohort of 285 consecutive patients who underwent DPS during the study period, data were evaluated for 70 subjects who underwent surgery for pancreatic exocrine cancer (27 with SVT, 43 without SVT). The preoperative demographics and co-morbidities were similar between the groups, except the average age was higher for those without SVT (p<0.05). The median estimated blood loss was significantly higher in the SVT group (675 versus 250 ml, p=<0.001).While the overall morbidity rates were similar between the two groups (48 % SVT versus 56% no SVT, p=NS), the group with SVT had a significantly higher rate of pancreas-specific complications, including pancreatic fistula (33 versus 7 %,p<0.01) and delayed gastric emptying (15 versus 0%, p<0.02). Hospital readmission rates were similar between the groups(30 versus 28 %, p=NS). Patients without SVT had a trend toward longer median survival (40 versus 20.8 months),although the difference was not statistically significant (p=0.1). DPS for pancreatic ductal adenocarcinoma can be performed safely in patients with SVT, but with higher intraoperative blood loss, increased pancreas-specific complications, and a trend towards lower long-term survival rates. This paper was presented as a poster at the 53rd annual meeting of the Society for Surgery of the Alimentary Tract and at the 46th annual meeting of the Pancreas Club, San Diego, CA, May 2012.

Entities:  

Mesh:

Year:  2013        PMID: 23797883     DOI: 10.1007/s11605-013-2260-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  17 in total

1.  Comprehensive analysis of variables affecting delayed gastric emptying following pancreaticoduodenectomy.

Authors:  John W Kunstman; Annabelle L Fonseca; Maria M Ciarleglio; Xiangyu Cong; Abby Hochberg; Ronald R Salem
Journal:  J Gastrointest Surg       Date:  2012-03-27       Impact factor: 3.452

2.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

4.  The epidemiology of pancreatic cancer in the United States: changes below the surface.

Authors:  Y H Shaib; J A Davila; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2006-07-01       Impact factor: 8.171

5.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

6.  American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma.

Authors: 
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

7.  Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area.

Authors:  Elizabeth A Holly; Indranushi Chaliha; Paige M Bracci; Manjushree Gautam
Journal:  Clin Gastroenterol Hepatol       Date:  2004-06       Impact factor: 11.382

8.  Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.

Authors:  Sarah E Greer; J Marc Pipas; John E Sutton; Bassem I Zaki; Michael Tsapakos; Thomas A Colacchio; Jennifer J Gibson; Daniel C Wiener; Gregory H Ripple; Richard J Barth
Journal:  J Am Coll Surg       Date:  2007-12-27       Impact factor: 6.113

9.  A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes?

Authors:  Timothy I Carter; Zhi Ven Fong; Terry Hyslop; Harish Lavu; Wei Phin Tan; Jeffrey Hardacre; Patricia K Sauter; Eugene P Kennedy; Charles J Yeo; Ernest L Rosato
Journal:  J Gastrointest Surg       Date:  2012-07-14       Impact factor: 3.452

10.  The natural history of pancreatitis-induced splenic vein thrombosis.

Authors:  T Ryan Heider; Samreen Azeem; Joseph A Galanko; Kevin E Behrns
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

View more
  6 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

2.  Repeated pancreatitis-induced splenic vein thrombosis leads to intractable gastric variceal bleeding: A case report and review.

Authors:  Shan-Hong Tang; Wei-Zheng Zeng; Qian-Wen He; Jian-Ping Qin; Xiao-Ling Wu; Tao Wang; Zhao Wang; Xuan He; Xiao-Lei Zhou; Quan-Shui Fan; Ming-De Jiang
Journal:  World J Clin Cases       Date:  2015-10-16       Impact factor: 1.337

3.  Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors.

Authors:  Laura Prakash; Jeffrey E Lee; James Yao; Priya Bhosale; Aparna Balachandran; Huamin Wang; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2015-08-18       Impact factor: 3.452

4.  Pancreatic neuroendocrine tumor with splenic vein tumor thrombus: A case report.

Authors:  Rodrigo A Rodriguez; Heidi Overton; Katherine T Morris
Journal:  Int J Surg Case Rep       Date:  2014-11-18

Review 5.  The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues.

Authors:  Elena Campello; Anton Ilich; Paolo Simioni; Nigel S Key
Journal:  Br J Cancer       Date:  2019-07-22       Impact factor: 7.640

6.  Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.

Authors:  Dominique Gantois; Théophile Guilbaud; Ugo Scemama; Edouard Girard; Olivier Picaud; Marine Lefevre; Myriam Elgani; Zeinab Hamidou; Vincent Moutardier; Paul Balandraud; Mircea Chirica; Louise Barbier; David Fuks; David Jérémie Birnbaum
Journal:  Langenbecks Arch Surg       Date:  2021-08-10       Impact factor: 2.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.